ConductScience.org, home

Comparison · NCT00527787-a1f5bbb0

PN400 (VIMOVO) vs Naproxen: Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. PN400 (VIMOVO) vs Naproxen: Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit. Trial comparisons, record NCT00527787-a1f5bbb0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00527787-a1f5bbb0

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.6420.5770.703wilson
Risk in group 20.3010.2440.365wilson
Risk difference, group 1 minus group 20.3410.2490.425newcombe hybrid score
Risk ratio, group 1 over group 22.131.72.68log
Odds ratio, group 1 over group 24.172.796.23log
Number needed to treat, for one more participant with the outcome on PN400 (VIMOVO) than on Naproxen2.932.354.01from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1PN400 (VIMOVO)Naproxen 500 mg/Immediate-Release Esomeprazole 20 mg140218OG000
Group 2NaproxenNaproxen 500 mg65216OG001

Outcome

Type
SECONDARY
Title
Heartburn Symptom Resolution, ie no Heartburn Symptoms During the Last 7 Days Prior to the Visit
Description
Subjects were asked whether heartburn symptoms within the 7 days prior to the visit were:~* none: no symptoms~* mild: awareness of symptom, but easily tolerated~* moderate: discomforting symptom sufficient to cause interference with normal activities (including sleep)~* severe: incapacitating symptom, with inability to perform normal activities (including sleep) Heartburn was defined as a burning feeling rising from the stomach or lower part of the chest towards the neck.
Time frame
6 months
Population
Intent to Treat (ITT) Population

Source ClinicalTrials.gov

Trial

Title
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
NCT number
NCT00527787
Phases
PHASE3
Conditions
Gastric Ulcer
Interventions
PN400 (VIMOVO), Naproxen
Lead sponsor
POZEN
Results first posted
2010-12-28

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT00527787-a1f5bbb0